Here we further demonstrated that the addition of circulating TSP2 levels to conventional clinical variables also significantly improved the prediction of HHF over years in type 2 diabetes, potentially allowing early HF risk stratification and treatment prioritization. This evidence concerns the gene THBS2 and hydrops fetalis.